Primary liver cancer is the sixth most common cancer and the third most common cause of
cancer-related deaths worldwide. Hepatocellular carcinoma (HCC) is a major histologic type …

Tumor vessel co-option (VCO) is a non-angiogenic vascularization mechanism that is a
possible cause of resistance to anti-angiogenic therapy (AAT). Multiple tumors are …

The liver is the most common metastatic site in colorectal cancer (CRC) patients. Indeed, 25–
30% of the cases develop colorectal liver metastasis (CLM), showing an extremely poor 5 …

Aims Vessel co-option is responsible for tumor resistance to antiangiogenic therapies
(AATs) in patients with colorectal cancer liver metastasis (CRCLM). However, the …

PCSK9 is a serine protease that regulates plasma levels of low-density lipoprotein (LDL)
and cholesterol by mediating the endolysosomal degradation of LDL receptor (LDLR) in the …

Colorectal cancer liver metastases (CRCLMs) have two major histopathological growth
patterns (HGPs): desmoplastic (DHGP) and replacement (RHGP). The DHGP tumours …

Simple Summary Vessel co-option has been recognized as a mechanism associated with
resistance to anti-angiogenic treatment in colorectal cancer liver metastases (CRCLMs) …

Hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancers and is the
third leading cause of cancer-related mortality worldwide. Multifactorial drug resistance is …

Colorectal cancer liver metastases (CRCLMs) have two main histopathological growth
patterns (HPGs): desmoplastic (DHGP) and replacement (RHGP). The vascularization in …

Tumor vasculature is pivotal in regulating tumor perfusion, immune cell infiltration,
metastasis, and invasion. The vascular status of the tumor is intricately linked to its immune …